Solvex (Bromhexine)

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solvex (Bromhexine)

Property Description
Active ingredient Bromhexine hydrochloride
Form Tablets, Oral Solution (Syrup), Injectable Ampoules
Pharmacological class Mucolytic Agent, Secretolytic Agent
General purpose To reduce the viscosity of thick respiratory secretions
Origin Synthetic compound

What is Solvex (Bromhexine) and What is its Classification?

Solvex is a medicinal preparation whose core component is the active ingredient Bromhexine hydrochloride, a widely utilized synthetic compound. The substance is officially classified as a mucolytic agent and secretolytic agent. This classification identifies its primary function: to act systemically by chemically modifying thick secretions. Bromhexine is a single-ingredient product derived structurally from the alkaloid vancisine, although the final drug is entirely manufactured through chemical synthesis.

Bromhexine's designation as a mucolytic agent is based on its ability to target and thin secretions. This foundational knowledge confirms its specific role in managing respiratory conditions associated with abnormal or excessive mucus secretion.


Solvex (Bromhexine): Available Forms and General Therapeutic Purpose

The preparation is offered in several distinct pharmaceutical preparations, primarily including solid-dose tablets and various liquid forms such as oral solution and syrup, which allows for flexible oral administration. The general therapeutic purpose is to address secretory dysfunction by focusing on the viscosity of tenacious mucus in the respiratory tract.

Bromhexine achieves this by promoting the depolymerization of mucopolysaccharides within the phlegm, which effectively liquefies the secretions. This crucial mechanism assists the body in maintaining a clear airway by ensuring that the viscous mucus can be more easily transported and expelled from the lungs, a process essential for unobstructed breathing. This is particularly relevant in scenarios where the mucus is excessively sticky, making a simple cough ineffective.

What side effects are possible with Solvex (Bromhexine)?

Possible Side Effects and Safety Information

The safety profile for Solvex (Bromhexine) is structured by regulatory bodies to communicate documented adverse reactions and specific safety constraints. The classification of side effects is based on frequency, grouping them by the body system affected.

Documented Adverse Reactions

The most commonly observed reactions are related to the Gastrointestinal disorders system, officially classified as Uncommon (occurring in 1/1,000 to <1/100 people). These include nausea, vomiting, diarrhoea, and upper abdominal pain.

Reactions affecting the Skin and subcutaneous tissue disorders and the Immune system disorders are generally classified as Rare or Not Known (cannot be estimated from the available data).

Classification Examples of Reactions
Rare Hypersensitivity reactions, Rash, Urticaria
Not Known Anaphylactic reactions (including anaphylactic shock), Angioedema, Bronchospasm, Severe cutaneous adverse reactions (SCARs)

Serious Adverse Reactions and Safety Constraints

Official labeling documents Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome and Toxic epidermal necrolysis, as rare but serious events. Symptoms of SCARs may be preceded by non-specific illness (prodrome) possibly occurring during the early phase of treatment.

Safety usage is constrained for specific patient populations and conditions. Caution is advised for patients with a history of or existing gastric/peptic ulceration or bronchial asthma. Use during pregnancy, especially the first trimester, and during lactation is generally avoided due to insufficient safety data or the potential risk to the infant. Individuals with severe hepatic or renal impairment should also use the medicine with caution, as clearance of the drug may be reduced.

Overdose and Emergency Response

Overdose and when to seek help

The following information is strictly based on the official overdose sections of government regulatory documents.

Overdose Scope

Documented Overdose Presentations No specific overdose symptoms have been reported in humans; observed signs are generally consistent with the known mild adverse effects of the medicine.
Physiological Systems Affected Reported symptoms primarily involve the gastrointestinal system (e.g., nausea, vomiting, diarrhea, and upper abdominal pain) and the nervous system (headache and dizziness).
Exposure-Related Factors Symptoms noted are mainly linked to situations involving accidental overdose or medication errors where higher doses were ingested.
Population-Specific Notes Official documents do not explicitly detail unique overdose manifestations or severity for specific populations (e.g., pediatric, elderly) in the dedicated overdose section.
Emergency-Response Statements Management requires symptomatic and supportive treatment. There is no specific antidote known to counteract the effects of Bromhexine overdose.
Immediate Medical Help Required Individuals must seek immediate medical advice or contact a doctor, pharmacist, or a Poisons Information Centre immediately upon suspected overdose.

Overdose Classifications (High-Level)

Severity Classification Severity is defined by the manifestation of known, mild adverse effects rather than unique toxicological signs.
Overdose-Context Constraints The regulatory context is constrained by the official finding that no unique toxicological effects beyond known adverse reactions are typically reported.

Resulting Overdose Structure

Official overdose statements:

  • Immediate medical advice or contact with emergency services is required in all cases of suspected overdose.
  • Observed overdose presentations are not unique and are consistent with known adverse effects, primarily involving gastrointestinal disturbances and headache.
  • Treatment is strictly defined as symptomatic and supportive measures, as no specific antidote is known.

Connection to the overall overdose profile: The regulatory documents define the overdose profile by the absence of specific, unique toxicological signs, focusing instead on the potential for intensified known gastrointestinal and nervous system effects. This finding officially mandates the requirement to seek immediate medical advice for professional evaluation and the application of symptomatic and supportive treatment, as no counteracting antidote is listed in the official prescribing information.

Therapeutic Uses of Solvex (Bromhexine)

What Solvex (Bromhexine) treats: main uses and benefits

Solvex is commonly used to help with the symptomatic relief of productive coughs (chesty coughs) where the main problem is thick, tenacious phlegm that is hard to bring up. The therapeutic use of this medication is associated with conditions marked by increased physiological stress, including acute and chronic bronchitis and other respiratory conditions that present with disruptive symptom manifestations.

This medication is applied in addressing symptom clusters that may become intense or disruptive, especially when retained mucus leads to symptoms related to physical discomfort. It provides support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms become more noticeable. In these situations, Solvex is relevant for easing symptoms that interfere with daily functioning when symptoms lead to temporary functional strain or discomfort.

“It contributes to improved comfort during periods of heightened symptoms and offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Chesty Cough

Regulatory References

  1. Australian Therapeutic Goods Administration monograph

Eligibility and Restrictions for Use

Regulatory information establishes specific eligibility rules for Solvex (Bromhexine) across different population groups. Use is contraindicated in patients with a known hypersensitivity to bromhexine hydrochloride or any excipients in the formulation. Furthermore, the medicine is not recommended for use in children under 6 years of age.

Official Eligibility Constraints

Classification Status Affected Population
Absolute Contraindication Contraindicated Hypersensitivity, Hereditary Fructose or Galactose Intolerance.
Conditional Use Caution Patients with severe hepatic impairment, severe renal impairment, or a history of gastric ulceration.
Age Restriction Conditional Children 6–11 years (use restricted to consultation with a healthcare professional).
Physiological Status Not Recommended Pregnant and breastfeeding women.

Use is generally approved for adults and children 12 years and over. Official labeling advises caution when used in patients with severe impairment of liver or kidney function, as well as those with a history of peptic or gastric ulceration. Use is not recommended during pregnancy or lactation due to limited safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific interactions of bromhexine with certain classes of medicinal products, primarily focusing on how bromhexine influences the distribution of other drugs in the body and its altered clearance in specific patient populations.

Pharmacokinetic Interactions

Interaction Domain Affected Medicines Constraint or Requirement
Effect on Concomitant Drug Exposure Antibiotic agents, including amoxicillin, cefuroxime, erythromycin, and doxycycline Co-administration leads to increased antibiotic concentration in lung tissue and bronchopulmonary secretions.
Clearance in Organ Impairment Bromhexine and its metabolites Clearance may be reduced in patients with severe hepatic impairment or severe renal failure. Use with caution is required.

Some official sources state that no other clinically relevant unfavorable interactions with other medicines have been consistently reported. The primary documented interaction is the enhancing effect on the concentration of co-administered antibiotics in the respiratory tract. This effect is relevant in the clinical management of respiratory infections where targeted antibiotic delivery is desired. The official profile also includes a special constraint for use in patients with severe liver or kidney disease, where reduced elimination of bromhexine or its metabolites may occur, which requires cautious application.

Mechanism of Action

Molecular Targets and Mucus Rheology

Solvex, functioning as a secretolytic agent, acts primarily by inducing the depolymerization of acid mucopolysaccharide fibers within the bronchial secretions. This structural change results in the reduction of mucus viscosity and elasticity.

Serous Secretion and Ciliary Function

Its primary active metabolite, Ambroxol, modulates serous gland secretion, leading to an increase in the serous fluid-to-mucus ratio within the respiratory tract. This combined biophysical change lowers the rheological resistance of the airway lining fluid, which subsequently enhances mucociliary transport by facilitating the effective movement of cilia.

Additional Cellular Interactions

Bromhexine has also been observed to interact with specific cellular targets. It can inhibit the transmembrane protease serine 2 (TMPRSS2) receptor and has been shown to modulate angiotensin-converting enzyme 2 (ACE2) activity, representing secondary cellular interactions beyond its core secretolytic function.

Dosage and Administration Information

Solvex (Bromhexine) is administered via the oral route, utilizing two primary dosage forms: immediate-release tablets and various liquid solutions or syrups. These routes and dosage forms facilitate systemic delivery of the active ingredient.

Standard Administration and Frequency

The standard adult regimen for patients over 12 years of age is typically 8 mg taken as a single dose, repeated three times daily. An initial single dose of up to 16 mg may be used for the first seven days of treatment. Regardless of the timing, liquid preparations must be accurately measured using the calibrated measuring device supplied with the product.

Administration can occur with or without food. If a dose is missed, the patient should skip the missed dose and resume the normal schedule, with double dosing prohibited to compensate for the skipped interval. Furthermore, the medicine is intended for short-term use only, with self-treatment generally limited to a course not exceeding seven consecutive days.

Age-Specific Use

Specific regimens exist for younger age groups. Children aged 6 to 11 years typically receive 4 mg to 8 mg three times daily. Use in children under two years of age is restricted and requires medical supervision. Administration typically excludes the concurrent use of cough-suppressant medications.

Recent Clinical Evidence

Solvex (Bromhexine): Recent Clinical Evidence

Bromhexine is classified as a mucolytic agent used to thin and loosen mucus in the airways. It is typically utilized for conditions where thickened bronchial secretions hinder breathing, such as acute and chronic bronchopulmonary diseases. The therapeutic action is thought to involve the activation of serous glands in the respiratory tract, increasing the volume and reducing the viscosity of bronchial secretions.


Clinical Efficacy Overview

Research has explored the clinical utility of bromhexine across various respiratory conditions. A meta-analysis examining its use in acute respiratory infections found that treatment was associated with improvements in measures of sputum volume and viscosity compared to placebo. Studies also evaluated the duration of cough and the ease of expectoration, noting a documented change in these endpoints in participants receiving the agent.


Tolerability Profile

Based on available clinical trial data, bromhexine is generally considered to be well tolerated when used as directed. The most commonly reported side effects observed across studies are typically mild and transient.

Side Effect Category Frequently Documented Examples
Gastrointestinal Nausea, vomiting, diarrhea
Hypersensitivity Skin rash, itching

Serious adverse events are reported to be rare. Participants with pre-existing conditions, such as a history of peptic ulcer disease, should seek guidance from a healthcare professional, as research has indicated the need for caution in these groups due to the drug's effect on mucus membranes.

Key Studies & References

  1. Product information for Ambroxol and Bromhexine expectorants to be updated (Risk of SCARs - Regulatory Safety Update)
  2. Summary of Product Characteristics (Example national label for Bromhexine products)

Frequently Asked Questions (FAQ)

Common questions about Solvex (Bromhexine) (FAQ)


Q: Is Solvex the same as other cough or cold medicines?

Solvex (Bromhexine) is officially classified as a mucolytic agent, meaning its primary function is to thin and loosen mucus. This function is distinct from that of a cough suppressant, which works by blocking the cough reflex. Official constraints advise against taking Solvex concurrently with cough-suppressant medicines.

Q: Is Solvex safe to use if I'm pregnant or breastfeeding?

Regulatory documents state that the use of Solvex (Bromhexine) is not recommended during pregnancy or lactation. This guidance is based on limited or insufficient safety data regarding its use in these specific populations.

Q: Does Solvex interact with common pain relievers like ibuprofen or acetaminophen?

Official prescribing information reports no clinically relevant unfavorable interactions with common, non-antibiotic medicines. The primary documented interaction is with certain antibiotics, where Solvex may increase antibiotic concentration in the lung tissue.

Q: What do regulatory documents say about using Solvex for conditions like asthma or COPD?

The medicine is indicated for use in chronic bronchopulmonary diseases associated with thickened secretions. However, official guidance advises that caution is used for patients with a pre-existing condition of bronchial asthma.

Q: What should I do if I think I've taken too much Solvex?

Regulatory documents state that no specific overdose symptoms have been consistently reported. Any observed symptoms are generally consistent with known side effects and may require symptomatic treatment. In the event a person suspects they have taken too much, official guidance is available for managing such situations.

Q: Are there specific symptoms that mean Solvex should be stopped immediately?

Yes. Official guidance states that if symptoms of Severe Cutaneous Adverse Reactions (SCARs) occur, the medicine is indicated to be discontinued without delay. These rare but serious events can appear as a progressive skin rash or new lesions on the mucous membranes.

Q: What constraints apply to the use of Solvex for people with liver or kidney problems?

Official guidance advises caution for individuals with severe impairment of liver or kidney function. This is because the clearance (elimination) of the drug or its metabolites may be reduced under these conditions.

Q: What are the regulatory constraints on using Solvex with other cold and flu products?

Official constraints advise against concurrent use with cough-suppressant medicines. Aside from this, regulatory documents generally report no other clinically relevant unfavorable interactions with other medicines often found in cold and flu products.

Q: Why does Solvex make me feel like I have to cough more after taking it?

The drug functions to thin mucus and activate mucociliary clearance—the system that moves mucus out of the airways. This biological effect facilitates the expulsion of secretions, which may temporarily increase the feeling of the need to cough as the body clears the now-loosened phlegm.

Q: How long does it typically take before I start noticing any effect from Solvex?

While the drug is rapidly absorbed into the body, clinical effects are generally reported to be observed after 2 to 3 days of consistent use. Solvex is intended to be used over a short course to help manage thick mucus.

Q: Are there any common foods or drinks that should be avoided when taking Solvex?

Regulatory guidance often states that the medicine can be taken with or without food. There are no specific common food restrictions listed in official regulatory documents.

Q: Is it true that Solvex is used for conditions other than just cough and mucus?

The authorized indications primarily relate to the management of bronchopulmonary diseases (conditions affecting the lungs and airways) and other states associated with excessive or thickened mucus secretions.

Q: Does taking Solvex make you drowsy or tired?

Drowsiness is not consistently listed as a common side effect in single-ingredient product information. However, regulatory documents do list occasional side effects such as dizziness and headache under Nervous system disorders.

Q: Can older adults use Solvex without special concerns?

The drug is widely used, and extensive clinical experience has not raised specific safety concerns regarding its use in older adults. However, regulatory documents note that no specific pharmacokinetic data is available for this exact population.

Q: How long can I generally continue taking Solvex?

For self-treatment, the medicine is officially intended for short-term use only. Official guidance specifies that a course should typically not exceed seven to ten consecutive days without medical guidance.

Q: What are the ingredients in Solvex besides Bromhexine?

The active ingredient is Bromhexine. Regulatory documents list all inactive ingredients (excipients) of the specific formulation (e.g., tablets or syrup), which can include components like sugars, colors, or stabilizers.

Q: Is a prescription needed to buy Solvex?

The regulatory status of bromhexine-containing medicines varies by region and formulation. In many countries, they are available as over-the-counter (OTC) products, while in others, they may be prescription-only medicines (POM).

Q: Is Solvex suitable for people with diabetes?

Suitability for people with diabetes often depends on the inactive ingredients (excipients) of the specific formulation. Liquid versions, in particular, may contain sugars, and these details are listed in the official product documents.

Q: Why do some people say Solvex helps them breathe better?

Official documentation describes the drug’s core function as reducing the viscosity of mucus and enhancing mucociliary transport. This action facilitates expectoration and eases cough, thereby promoting the clearance of the airways, which users may perceive as easier breathing.

Q: Does Solvex have an expiration date, and is it still good after that?

Yes, all regulatory documents specify a shelf life (expiration date) for the medicinal product. This date ensures that the drug's quality, stability, and efficacy are maintained until that time.

Q: How is Solvex processed by the body?

Official documents describe that the drug is readily absorbed following oral intake. It undergoes extensive metabolism (broken down) primarily in the liver and is then mainly excreted in the urine as various metabolites.

Q: Does Solvex cause any issues with driving or operating machinery?

When used as recommended and without experiencing side effects, the medicine is not known to have any effect on the ability to drive or operate machinery. However, caution is advised if the side effect of dizziness occurs.

Q: Are there any long-term side effects associated with Solvex use?

Official labeling documents and safety data are based on the drug's intended short-term use. Side effects reported are typically mild, and serious events like SCARs are rare events that can occur during the early phase of treatment.

Q: Are there different strengths of Solvex available?

Yes. Regulatory documents confirm the availability of different dosage forms and strengths. This includes solid forms like tablets (e.g., 8 mg) and liquid forms such as oral solutions, which come in different concentrations.

Q: What do regulatory documents say about interactions between Solvex and medications for anxiety or depression?

Official regulatory documents generally state that no clinically relevant unfavorable interactions with other medicines, including common psychotropic drugs (for anxiety or depression), have been consistently reported.

Q: Why do doctors sometimes suggest drinking extra water with Solvex?

Consumer information consistent with official guidance suggests drinking plenty of fluids while taking the medication. This is because good hydration helps to further loosen and thin mucus secretions, supporting the drug's action.

Q: Are there any reported interactions with alcohol and Solvex?

Some regulatory sources state that avoiding or limiting alcohol consumption is suggested. This is because alcohol may enhance some central nervous system side effects, such as drowsiness or dizziness.

Q: Do any official regulatory bodies classify Solvex (Bromhexine) as a high-risk drug?

Regulatory bodies classify the drug as generally well tolerated when used as directed. They acknowledge a low risk of rare but serious events, such as Severe Cutaneous Adverse Reactions (SCARs), which all drug manufacturers must document.

Q: How quickly is Solvex eliminated from the body?

The drug is primarily excreted in the urine, mainly as metabolites. Official documents report that the terminal elimination half-life (the time for half the drug to be eliminated) is up to about 12 hours.

Q: Can Solvex be crushed or chewed?

For the tablet formulation, official patient information often advises patients to swallow the tablet whole with water. Official guidance indicates that the tablet form is intended to be swallowed whole and should not be crushed, chewed, or broken.

Q: Is it normal for mucus to change consistency after taking Solvex?

Yes, this is the intended result of the drug's mechanism. The core function of the medicine is to reduce the viscosity and elasticity of bronchial secretions, which results in thinner, less viscous mucus that is easier to expel.

How should Solvex (Bromhexine) be stored and disposed of?

Solvex (bromhexine) must be stored according to official labeling to maintain stability and prevent environmental risk.

Storage Requirements

  • Temperature and Environment: Store the medicine in a dry place at a temperature below 25 C or room temperature. The product must be protected from light and excess heat. Do not refrigerate or freeze.
  • Container and Safety: Keep the product in its original container and ensure the cap or closure is tightly closed. The medicine must be kept out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused Solvex must be disposed of according to local regulations or via an authorized drug take-back program. Medicines must not be thrown away in the household trash unless specifically instructed, and should not be disposed of via wastewater (flushed down the toilet or drain) to avoid environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solvex (Bromhexine) found in:

A-Z Index: